http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0641353-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b2d9c5cdb9158c296274ecc21903f91 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-312 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 |
| filingDate | 1992-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfc9deed9c9e998cf8baa0bc08426d35 |
| publicationDate | 1995-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0641353-A1 |
| titleOfInvention | Anti-sense oligonucleotides for isotype-specific suppression of immunoglobulin production |
| abstract | The invention includes oligonucleotides which are complementary to the 3'-end untranslated regions or to at least some of the splicing recognition region of an mRNA transcript precursor for a particular immunoglobulin heavy chain. More particularly, the oligonucleotides are complementary to at least a continuous 12 nucleotide segment of the sequence upstream to the 3' splice junction up to and including the branch point A residue. Sequences of some of the oligonucleotides of the invention are the underlined portions of SEQ ID NOS: 3-33. These oligonucleotides will hybridize with the splicing recognition region and prevent or inhibit maturation of the mRNA. This will prevent production of mRNA encoding a complete immunoglobulin, so that it will not be translated into a functional immunoglobulin. The invention also pertains to the preparation of these anti-sense oligonucleotides for specifically suppressing IgG and/or IgM production in patients suffering from autoimmune diseases and for specifically suppressing IgE in patients suffering from allergic diseases manifested by immediate-type hypersensitivities. |
| priorityDate | 1991-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.